Get a quote

In Vivo Pharmacokinetics (PK)

Sygnature’s integrated and seamless approach to drug discovery combines our in-house expertise in in vivo pharmacology, offering a continuous oversight from study initiation to completion, thereby enhancing the likelihood and pace of achieving success. At Sygnature we offer services to support your non-GLP in vivo pharmacokinetics studies in preclinical rodent species, including the planning of these studies and the analysis of any samples generated by UPLC-MS.

Sample analysis includes a robust calibration curve comprising a minimum of 8 calibration standards, supplemented by independent Quality Control (QC) samples. Furthermore, the study design can incorporate the analysis of dose formulation concentrations.

The resultant data is condensed into a concise summary spreadsheet, featuring pertinent pharmacokinetics parameters as needed.

In the realm of In Vivo Pharmacokinetics (PK):

In vivo pharmacokinetic reports encompass the entirety of raw data, computations, and a summary table encapsulating calculated parameters. This includes key metrics such as clearance, volume of distribution, AUC, half-life (T1/2), Cmax, Tmax and bioavailability. These calculations adhere to industry norms, utilising WinNonLin or equivalent software for NCA and PK/PD modelling and simulation.

Sygnature is deeply committed to championing the principles of the 3Rs – Replacement, Reduction, and Refinement – in our scientific endeavours.

Latest News

View All

Sygnature Discovery Receives EcoVadis Award For Sustainable…

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…